Health Canada approves aflibercept biosimilar Aflivu

News
Article

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Ottawa, Ontario, Canada - August 8, 2020: Health Canada sign at 100 Eglantine Drwy office in Ottawa on August 8, 2020. Health Canada is the department of the Government of Canada. (Image credit: ©JHVEPhoto/AdobeStock)

(Image credit: ©JHVEPhoto/AdobeStock)

Health Canada has approved Aflivu (aflibercept), a biosimilar to Eylea, indicated for the treatment of neovascular age-related macular degeneration (AMD), macular oedema secondary to central or branch retinal vein occlusion (RVO), treatment of diabetic macular oedema (DME), and treatment of myopic choroidal neovascularization.

According to the press release1 issued by Apotex, this approval marks the Canadian-based global health company’s first ophthalmic biosimilar and its fourth biosimilar since 2016. This expanding inventory of products is in line with the company’s intent to grow its biologics portfolio and execution of its Journey of Health strategy.

Raymond Shelley, President, Apotex Canada spoke to the impact this approval will have on Canadian patients, saying, "With Aflivu, we're expanding affordable treatment options for Canadians affected by retinal diseases. Apotex continues to deliver innovative, patient-focused solutions across our growing portfolio of brands, biosimilars, generics and consumer health products."1

Bernard R. Hurley, BSc, MD, FRCSC, Assistant Professor at the University of Ottawa Eye Institute is also quoted in the news release1, noting the importance of biosimilars: "The approval of Aflivu represents a positive advancement in ophthalmic care. Biosimilars, supported by clinicians, regulators, and manufacturers, have the potential to transform the treatment landscape for retinal diseases, preserving vision and providing quality, cost-effective care for countless Canadians."

"In clinical practice, having access to a broader range of therapeutic options can empower physicians to tailor care to individual patients' needs," said Ghassan Cordahi, MD, FACS, Assistant Clinical Professor, Faculty of Medicine, Department of Ophthalmology, Université de Montréal. "Aflibercept has been a cornerstone in managing retinal diseases, and the introduction of Aflivu offers a more affordable alternative without compromising quality."1

About Apotex

Apotex is a Canadian-based global health company. With a mission to improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Apotex is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.1

Reference:
1. Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats. Apotex Inc. July 2, 2025. Accessed July 7, 2025. https://www.prnewswire.com/news-releases/apotex-receives-health-canada-approval-for-aflivu-a-biosimilar-to-eylea-available-in-pre-filled-syringe-and-vial-formats-302496912.html


Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.